Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Medtronic (MDT) -- Ignore unavailable to you. Want to Upgrade?

To: Dennis who wrote (444)	2/8/2000 9:35:00 AM
From: Mike	Respond to of 687

Did anyone see this from GDT? Does this put GDT in the lead or is this announcement showing they are behind? MDT had started these clinicals sometime ago for PMA for Insynch. Is this what was required by the FDA or is this in additional study? Mike Guidant to study device for treating heart failure Monday February 7, 11:08 am Eastern Time INDIANAPOLIS, Feb 7 (Reuters) - Guidant Corp. (NYSE:GDT - news), one of the largest medical device companies, said on Monday that it is starting a new U.S. study on treatment for congestive heart failure, a cardiovascular disorder affecting millions around the world. The study, called COMPANION, follows Food and Drug Administration approval. Guidant is one of several medical device makers targeting the heart failure population. Heart failure is characterized by a gradual loss of pumping efficiency, leading to a number of problems including trouble breathing, fluid retention and sometimes inability to live a normal life or carry out daily routines. Guidant said heart failure affects well over 5 million people in the United States and an estimated 6.5 million in Europe. Nearly 1 million new cases are diagnosed annually, making it the most rapidly growing cardiovascular disorder. ``COMPANION is designed to help answer important questions associated with the use of implantable devices as new heart failure therapy,' said Jay Graf, president of Guidant's Cardiac Rhythm Management Group. ``Patients will be randomized to receive drug therapy alone or drug therapy in combination with implantable devices that resynchronize heart rhythms.' The study will collect and evaluate clinical data on more than 2000 patients in up to 80 centers across the U.S. to help determine the best medical therapy for heart failure patients. Dr. Arthur Feldman, President of the Heart Failure Society of America and professor at the University of Pittsburgh and Dr. Michael Bristow, professor at the University of Colorado, are running the study. It will evaluate several areas including ability to exercise, quality of life, length and frequency of hospitalization and survival rates. Products to be evaluated include Guidant's CONTAK CD and TR pulse generators and the EASYTRAK lead, a patented transvenous lead system implanted in the coronary vessels to coordinate stimulation of the left side of the heart with the right side. ``Our early experience in Europe indicates that the CONTAK/EASYTRAK system can provide clinical benefit in the treatment of patients who suffer from chronic heart failure,' Graf said. Guidant's heart failure treatment systems have been sold in Europe since last November.

To: Dennis who wrote (444)	2/17/2000 5:38:00 PM
From: Volsi Mimir	Read Replies (1) \| Respond to of 687

Howdy Dennis Yesterdays news about MDT biz.yahoo.com New England Journal of Medicine Study Reports Advantages of Thalamic Stimulation Over Thalamotomy for Suppressing Tremor saw a very fascinating presentation of this on the local cable extension channel in Seattle from University of Washington that told of the proceedure and had a lady on that had that implanted in her and showed what happens when it was on/off -- her hand was very still and she was very grateful to be able to be independent because of that-- she couldn't hold a cup or write-- both tried. I thought it was local so I didn't pay attention to the credits at the end except it had Medtronic showing.... hopefully that would show up in your area. RBOT will be reporting sometime next week and it would be interesting if it coincides with MDT's wed E$-report. (a dose of hopeful speculation since poor little RBOT has been very quiet for a long time) Anyways the main point was the presentation and seening it actually work and helping was my intrusion on this thread. (am looking at MDT now -- missed yesterdays little pullback) PS look at BONZ -- solid little company-- dont know if this is a good time to get in (in at 9) but maybe put it on watch crow ~.~